Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Kymera Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Kymera Therapeutics's price to sales ratio was 106.3× on Nov 11, 2026, against 111.3× a year earlier. Over the last 5 years it ranged from 11.6× to 189.5×, with a median of 34.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 106.3× | −21.3 |
| 2025 | Dec 31, 2025 | 127.6× | +97.9 |
| 2024 | Dec 31, 2024 | 29.7× | −0.4 |
| 2023 | Dec 29, 2023 | 30.1× | +0.4 |
| 2022 | Dec 30, 2022 | 29.7× | −16.5 |
| 2021 | Dec 31, 2021 | 46.3× | −73.1 |
| 2020 | Dec 31, 2020 | 119.4× | – |
See a number that looks wrong?